October 2011

Life sciences

 

MyHealthyWaist Revolutionizes Cardiometabolic Risk Evaluation

MyHealthyWaist Revolutionizes Cardiometabolic Risk Evaluation

The International Chair on Cardiometabolic Risk of Université Laval in partnership with Nurun,  announced the launch of MyHealthyWaist, an iPad application designed especially for health professionals.

 

Researcher of the Year in Family Medicine - France Légaré honored by the CFPC

Researcher of the Year in Family Medicine - France Légaré honored by the CFPC

Again this year, several members of the Department of Family Medicine and Emergency Medicine were able to distinguish themselves by receiving prizes and scholarships from the College of Family Physicians of Canada. Among the recipients of 2011, Professor France Légaré garnered the prestigious researcher of the year in family medicine.

 

TSO3 files for commercial clearance in the United States

TSO3 files for commercial clearance in the United States

TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, announced today that it has resubmitted documentation to the United States regulatory authorities for the company's STERIZONE® 125L+ Sterilizer. Such a filing is in support of obtaining clearance for the new generation sterilizer to be sold within the United States.

 

Aeterna Zentaris Granted Patent for Perifosine by European Patent Office

Aeterna Zentaris Inc. today announced that the European Patent Office has granted a patent for the use of alkyl phosphocholines, more specifically perifosine , in the preparation of a medicament for the treatment of benign and malignant tumours, prior to and/or during the treatment with approved anti-tumour anti-metabolites such as 5FU and capecitabine.

 

Health Canada Approves BENLYSTA(TM)

Health Canada Approves BENLYSTA(TM)

For the first time in almost 50 years Canadians living with lupus have a new treatment option.  Health Canada has approved BENLYSTATM (belimumab), a new drug specific for the treatment of systemic lupus erythematosus (SLE, or simply lupus). The announcement was made today by GlaxoSmithKline Inc. (GSK) and Human Genome Sciences (HGS) who are developing BENLYSTATM under a co-development and co-commercialization agreement entered into in 2006. BENLYSTATM is expected to become available to patients in Canada in September of this year.

 

Medicago commences operations at its state-of-the-art vaccine facility in North Carolina

Medicago previously signed a US$21M Technology Investment Agreement with the Defense Advanced Research Projects Agency (DARPA) to develop a 90,000-square-foot vaccine facility in Research Triangle Park (RTP), North Carolina. This state of-the-art facility is a large, cost-effective and scaled-up facility for Medicago's VLP plant-based vaccine technology ultimately for the delivery of current good manufacturing practice (cGMP)-grade vaccine. Medicago intends to demonstrate its capacity to produce 10 million doses/month of influenza vaccines with the potential for further expansion in the future.

 

Canada’s first research chair in bariatric and metabolic surgery

The chair's several goals will include optimizing management practices for patients awaiting bariatric surgery, improving post-operative monitoring, and developing minimally invasive therapeutic interventions for those suffering from severe obesity.

 

A Quebec researcher obtains a $2 million grant to fight antibiotic resistance

Dr. Michel G. Bergeron and his team of researchers from the Centre de recherche du CHUQ have obtained a $2 million grant from the Quebec Consortium for Drug Discovery (CQDM) for their research project on antibiotic resistance.

 

Test Based on DiagnoCure’s PCA3 Biomarker Obtains Canadian Regulatory Approval

DiagnoCure, a life sciences company that develops and commercializes high‐value cancer diagnostic tests, today announced that Health Canada has granted Gen‐Probe, the Company's commercial partner for the PCA3 biomarker, a medical device license for the PROGENSA® PCA3 assay, a new molecular urine test that helps determine the need for repeat biopsies in men suspected of having prostate cancer.

 

Atrium Innovations Announces Acquisition of Enzimas S.A.

Atrium Innovations today announced the acquisition of Enzimas S.A., a manufacturer of Trypsin and Chymotrypsin enzymes based in Lujan, Argentina. The Company acquires a manufacturing facility and process that is approved by various regulatory bodies in countries where Wobenzym products are sold. This acquisition was aimed at securing two critical enzymes, which are in relatively short supply worldwide in the quality required for the formulation of Wobenzym products.

 

Medicago Wins Frost & Sullivan's 2011 North American Enabling Technology Award in the Vaccines market

Medicago Wins Frost & Sullivan's 2011 North American Enabling Technology Award in the Vaccines market

The award was the result of Frost & Sullivan's discussions with clients, industry influencers, and technology vendors throughout the year, as well as an objective, comparative analysis of several companies' performance based on quantitative and qualitative metrics along several criteria including development of new products, enhancement of current products, delivery of new applications, and market acceptance.

 

Government of Canada Supports Innovation to Prevent Soldier Injuries

Canadian soldiers may soon benefit from a new technology that prevents muscle and bone injuries from carrying heavy combat gear during field operations, thanks to an investment from the Government of Canada. Funding was announced today for Quebec-based B-Temia Inc. by the Honourable Christian Paradis, Minister of Industry.